Amsterdam, October 23, 2014 - Herbal medicines such as licorice, Indian rennet and opium poppy, are at risk of contamination with toxic mould, according to a new study published in Fungal Biology. The authors of the study, from the University of Peshawar, Pakistan say it's time for regulators to control mould contamination.
An estimated 64% of people use medicinal plants to treat illnesses and relieve pain. The herbal medicine market is worth $60 billion globally, and growing fast. Despite the increasing popularity of herbal medicine, the sale of medicinal plants is mostly unregulated.
The new study analyzes toxic mould found on common medicinal plants in the Khyber Pakhtunkhwa province of Pakistan, where the majority of people use herbal medicine. They found that around 43% of the plants were naturally contaminated with toxins, produced by moulds that could be harmful to human health. 30% of the samples contained aflatoxins, which are carcinogenic and linked to liver cancer, and around 26% were contaminated with ochratoxin A, which is toxic to the liver and kidneys, and can suppress the immune system.
"It's common to use medicinal plants in our country and to buy from local markets and shops," said Ms. Samina Ashiq, one of the authors of the study from the University of Peshawar. "There's a common misconception that just because they're natural, the plants are safe. We knew from experience that this wasn't the case, but we wanted to really test it and quantify the contamination."
Ms. Ashiq and the team analyzed 30 samples of plants known for their medicinal properties, including licorice, Indian rennet and opium poppy. They found that 90% of the samples were contaminated with mould, and the levels exceeded permissible limits in 70% of the samples.
They then grew the moulds to find out if they produced toxins that could be harmful to human health. 19% of the moulds produced aflatoxins, and 12% produced ochratoxin A. Overall, 31% of the moulds growing on the plants they tested produced harmful toxins.
"These results are a clear indicator that we need more stringent regulation in place," continued Ashiq. "There is a real public health concern due to the lack of effective surveillance of the quality, safety and efficacy of these medicinal plants. It's time for regulators to step in and set limits to protect people who want to use herbal medicines like these."
The plants can become contaminated at each stage of production: during growth, handling, collection, transportation and storage. Those that are exported for sale may be contaminated before they reach their destination. In Pakistan and many other countries, these plants are primarily sold on markets where hygiene is not top priority.
"By setting limits to fungal contamination of these plants, Pakistan and other countries would be better able to export to places that do have controls in place. Hygienic processing and sale of medicinal plants is essential to protect people, and also if the economy is to benefit from the booming herbal medicine industry," added Ms. Ashiq.
This article is "Evaluation of mycotoxins, mycobiota, and toxigenic fungi in selected medicinal plants of Khyber Pakhtunkhwa, Pakistan" by Bashir Ahmada, Samina Ashiqa, Arshad Hussainb, Shumaila Bashirc, Mubbashir Hussaind (DOI: DOI: 10.1016/j.funbio.2014.06.002), Fungal Biology, published by Elsevier.
Notes for editors
Copies of the paper or accompanying editorial are available for journalists upon request or to schedule an interview with the lead author of the study, contact: firstname.lastname@example.org.
About Fungal Biology
Fungal Biology is the international research journal of the British Mycological Society. Fungal Biology publishes original contributions in all fields of basic and applied research involving fungi and fungus-like organisms (including filamentous fungi, yeasts, lichen fungi, oomycetes, and slime moulds). Priority is given to contributions likely to be of interest to a wide international audience. For more information: http://www.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey -- and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).